Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasquinimod Maintenance in mCRPC
NCT01732549Phase 2Terminated
- Sponsor
- Ipsen
- Start
- Jan 2013
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Tasquinimod with Placebo (2 arms). Primary endpoint: Radiological Progression Free Survival up to 2.5 years. Started Jan 2013; status: terminated.
02
Drugs
tasquinimod
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01732549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01732549.